bioRxivBioinformaticsPreprint
Novel Target Combinations in Lung Squamous Cell Carcinoma proposed by the Emet AI Research Environment and supported by discovery stage experimentation
Jyothish Soman, Jordan Newington, Simeon Wong, Nikita Desai, Sophia LeungiD, Juliana CudiniiD, Fernando SuareziD, Peter Grandsard, Arnab Kundu
Abstract
Early drug discovery is frequently bottlenecked by target identification, a challenge that becomes particularly difficult in complex diseases driven by overlapping, redundant pathways rather than a single dominant driver. Lung squamous cell carcinoma (LUSC) is one such disease: mutationally complex, lacking a dominant actionable target, and marked by a long series of failed single-agent targeted trials. We hypothesized a research environment, capable of reasoning across interconnected datasets, would be well-suited to generate novel, mechanistically grounded therapeutic hypotheses for LUSC. Emet, an AI research environment utilizing a biomedical knowledge graph of more than 1.5 billion triples connected to over 100 specialised biological databases, was paired with an Agentic Research Director that pursues each hypothesis through a graph-of-thoughts search, invoking scoped link-prediction and retrieval tools and committing every round of findings to persistent memory. The top-ranked hypotheses were two-target combinations rather than a single target. The four highest-ranked combinations were advanced to dose-matrix testing in NCI-H520 and SK-MES-1 cells, and two produced combination effects exceeding either single agent; to our knowledge neither of these two pairings had previously been evaluated in LUSC. Dual inhibition of CDC7 (TAK-931) and PKMYT1 (RP-6306) produced statistically significant synergy in both lines that strengthened from day 5 to day 7 (HSA 19.24 to 24.19 in NCI-H520; 11.07 to 13.73 in SK-MES-1). Dual inhibition of USP13 (spautin-1) and PI3K (alpelisib) produced an additive, cell-line-dependent effect, and immunoblotting confirmed the predicted mechanism: time-dependent depletion of MCL-1, c-Myc and SOX-2 driven by the USP13 arm. Agentic reasoning over multi-domain biomedical evidence can therefore nominate testable, mechanism-bearing combination hypotheses that survive experimental scrutiny.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Utilising multi-modal data-driven network analysis to identify monotherapy and combinational therapy targets in SOX2-dependent squamous cell lung cancer
Woochang Hwang, Daniel Kottmann, … Namshik Han·Communications ChemistryPeer-reviewed·Dec 12, 2025
- Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis
Verra M. Ngwa, Yoonha Hwang, … Jin Chen·Cancer Gene TherapyPeer-reviewed·Jul 10, 2025
- A landscape of synergistic drug combinations in non-small-cell lung cancer
N. U. Nair, P. Greninger, … C. H. Benes·bioRxiv·Jun 3, 2021
- BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous cell carcinoma
K. A. Lazarus, F. Hadi, … W. T. Khaled·bioRxiv·Nov 22, 2017
- USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinoma
E. J. Ruiz, A. Pinto-Fernandez, … A. Behrens·bioRxiv·Nov 17, 2020
- A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers
Meghri Katerji, Kailey N. Jackett, … John Brognard·bioRxiv·Oct 20, 2026